Kissei and JCR conclude accord on biosimilar Aranesp

1 October 2013

Japanese drugmakers Kissei Pharmaceutical and JCR Pharmaceuticals have announced the conclusion of a collaborative R&D agreement, for a biosimilar to a long-acting erythropoiesis stimulating agent, darbepoetin alfa (the active ingredient of biotech giant Amgen’s [Nasdaq: AMNG] Aranesp), for the treatment of renal anemia.

Kissei and JCR have jointly developed a biosimilar to a recombinant human erythropoietin, Epoetin alfa BS injection [JCR], a treatment agent for renal anemia. It was the first domestically-produced biosimilar in Japan. JCR has manufactured the product and Kissei has distributed it since May 2010.

Both companies are aiming to contribute to the improvement in medical treatment for renal anemia continuously through providing the new economically-efficient treatment option developed under this collaboration with JCR’s global standard quality assurance system and manufacturing system for bio-drugs and Kissei’s established presence in the dialysis field.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK